medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2008, Número 2

<< Anterior Siguiente >>

Ann Hepatol 2008; 7 (2)


Hepatitis B virus and Hepatocarcinogenesis

Azam F, Koulaouzidis A

Idioma: Ingles.
Referencias bibliográficas: 29
Paginas: 125-129
Archivo PDF: 145.71 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lok AS. Prevention of hepatitis B virus related hepatocellular carcinoma. Gastroenterology 2004; 127: S303-9.

  2. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.

  3. Cha C, Dematteo RP. Molecular mechanisms in hepatocellular carcinoma development. Best Pract Res Clin Gastroenterol 2005; 19: 25-37.

  4. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastrenterology 2004; 127: S35-50.

  5. Brechot C. Pathogenesis of hepatitis B virus related hepatocellular carcinoma: old and new paradigm. Gastroenterology 2004; 127: S56-61.

  6. Tanaka H, Iwasaki Y, Nouso K, Kobayashi Y, Nakamura S, Matsumoto E, Toshikuni N, et al. Possible contribution of prior hepatitis B virus infection to the development of hepatocellular carcinoma. J Gastroenterol Hepatol 2005; 20: 850-6.

  7. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, et al. Universal hepatitis B vaccination in Taiwan and incidence of hepatocellular carcinomain children. N Eng J Med 1997; 336: 1855-9.

  8. Lee MS, Kim DH, Kim H, Lee HS, Kim CY, Park TS, Yoo KY, et al. Hepatitis B vaccination and reduced risk of primary liver cancer among male adults: a cohort study in Korea. Int J Epidemiol 1992; 27: 316-19.

  9. Singh M, Kumar V. Transgenic mouse models of hepatitis B virus associated hepatocellular carcinoma. Rev Med Virol 2003; 13: 243-53.

  10. Pang R, Tse E, Poon RT. Molecular pathways in hepatocellular carcinoma. Cancer Lett 2006; 240: 157-69.

  11. Zhang SH, Cong WM, Xian ZH, Wu MC. Clinicopathological significance of loss of hetrozygosity and microsatellite instability in hepatocellular carcinoma in China. World J Gastroenterol 2005; 11: 3034-9.

  12. Wang Y, Lau SH, Sham JS, Wu MC, Wang T, Guan XY. Characterization of HBV integrants in 14 hepatocellular carcinoma: association of truncated x gene and hepatocellular carcinogenesis. Oncogene 2004; 23: 142-8.

  13. Tu H, Bonura C, Giannini C, Mouly H, Soussan P, Kew M, Paterlini-Bréchot P, et al. Biological impact of natural COOH-terminal deletion of Hepatitis B virus x protein in hepatocellular carcinoma tissues. Cancer Res 2001; 61: 7803-10.

  14. Pagano JS, Blaser M, Buendia MA, Damania B, Khalili K, Raab-Traub N, Roizman B. Infectious agents and cancer: criteria for a causal relation. Semin Cancer Biol 2004; 14: 453-71.

  15. Xu Z, Jensen G, Yen TS. Activation of hepatitis B virus S promoter by viral large surface protein via induction of stress in endoplasmic reticulum. J Virol 1997; 71: 7387-92.

  16. Murakami Y, Saigo K, Takashima H, Minami M, Okanoue T, Bréchot C, Paterlini-Bréchot P. Large scaled analysis of hepatitis B virus DNA integration in HBV related hepatocellular carcinomas. Gut 2005; 54: 1162-68.

  17. Park NH, Song IH, Chung YH. Chronic hepatitis B in hepatocarcinogenesis. Postgraduate Medical Journal 2006; 82: 507-15.

  18. Peng Z, Zhang Y, Gu W, Wang Z, Li D, Zhang F, Qiu G, Xie K. Integration of hepatitis B virus X fragment in hepatocellular carcinoma and its effect on the expression of multiple molecules: a key to the cell cycle and apoptosis. Int J Oncol 2005; 26: 467-73.

  19. Cheng AS, Chan HL, Leung WK, To KF, Go MY, Chan JY, Liew CT, et al. Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2. Mod Pathol 2004; 17: 1169-79.

  20. Lin Y, Nomura T, Yamashita T, Dorjsuren D, Tang H, Murakami S. The transactivation and p53-interacting functions of hepatitis B virus X protein are mutually interfering but distinct. Cancer Res 1997; 57: 5137-42.

  21. Wang XW, Gibson MK, Vermeulen W, Yeh H, Forrester K, Stürzbecher HW, Hoeijmakers JH, et al. Abrogation of p53-induced apoptosis by hepatitis B virus X gene. Cancer Res 1995; 55: 6012-16.

  22. Shintani Y, Yotsuyanagi H, Moriya K, Fujie H, Tsutsumi T, Kanegae Y, Kimura S, et al. Induction of apoptosis after switch-on of the hepatitis B virus x gene mediated by Cre/LoxP recombination system. J Gen Virol 1999; 80: 3257-65.

  23. Lee YI, Kang-Park S, Do SI, Lee YI. The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signalling cascade. J Biol Chem 2001; 276: 16969-77.

  24. Terradillos O, de La Coste A, Pollicino T, Neuveut C, Sitterlin D, Lecoeur H, Gougeon ML, et al. The hepatitis B virus X protien abrogates Bcl-2 mediated protection against Fas apoptosis in the liver. Oncogene 2002; 21: 377-86.

  25. Zhang X, Dong N, Yin L, Cai N, Ma H, You J, Zhang H, et al. Hepatitis B virus X protein upregulates surviving expression in hepatoma tissues. J Med Virol 2005; 77: 374-81.

  26. Miao J, Chen GG, Chun SY, Lai PP. Hepatitis B virus X protein induces apoptosis in hepatoma cells through inhibiting Bcl-xl expression. Cancer Lett 2006; 236: 115-24.

  27. El Far MA, Atwa MA, Yahya RS, El Basuni MA. Evaluation of serum p53 in HCC in Egypt. Clin Chem Lab Med 2006; 44: 653-56.

  28. Wee A, Teh M, Raju GC. p53 expression in hepatocellular carcinoma in a population in Singapore with endemic hepatitis B virus infection. J Clin Pathol 1995; 48: 236-8.

  29. Klein A, Guhl E, Tzeng YJ, Fuhrhop J, Levrero M, Graessmann M, Graessmann A. HBX causes cyclin D1 overexpression and development of breast cancer in transgenic animals that are heterozygous for p53. Oncogene 2003; 22: 2910-19.




2020     |     www.medigraphic.com